1/16/24, 2:09 AM
`
`Interactive Financials | Eli Lilly and Company
`
`Interactive Financials
`
`Income Statement
`
`Balance Sheet
`
`Cash Flow
`
`Timeframe:
`
`Annual
`
`Period:
`
`Current Financials
`
`Filter
`
` Download CSV
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Net Sales
`
`28,541.40
`
`28,318.40
`
`24,539.80
`
`22,319.50
`
`Revenue
`
`28,541.40
`
`28,318.40
`
`24,539.80
`
`22,319.50
`
`https://investor.lilly.com/financial-information/fundamentals/income-statement
`
`1/37
`
`Novo Nordisk Exhibit 2529
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00001
`
`
`
`Interactive Financials | Eli Lilly and Company
`
`Interactive Financials
`
`Income Statement
`
`Balance Sheet
`
`Cash Flow
`
`Timeframe:
`
`Annual
`
`Period:
`
`Current Financials
`
`Filter
`
` Download CSV
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Net Sales
`
`28,541.40
`
`28,318.40
`
`24,539.80
`
`22,319.50
`
`Revenue
`
`28,541.40
`
`28,318.40
`
`24,539.80
`
`22,319.50
`
`https://investor.lilly.com/financial-information/fundamentals/income-statement
`
`1/37
`
`Novo Nordisk Exhibit 2529
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00001
`
`
`
`1/16/24, 2:09 AM
`
`Interactive Financials | Eli Lilly and Company
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Total Revenue
`
`28,541.40
`
`28,318.40
`
`24,539.80
`
`22,319.50
`
`Cost of Revenue
`
`6,629.80
`
`7,312.80
`
`5,483.30
`
`4,721.20
`
`Cost of Revenue, Total
`
`6,629.80
`
`7,312.80
`
`5,483.30
`
`4,721.20
`
`https://investor.lilly.com/financial-information/fundamentals/income-statement
`
`2/37
`
`Novo Nordisk Exhibit 2529
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00002
`
`
`
`1/16/24, 2:09 AM
`
`Interactive Financials | Eli Lilly and Company
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Gross Profit
`
`21,911.60
`
`21,005.60
`
`19,056.50
`
`17,598.30
`
`Selling/General/Administrative Expense
`
`5,440.40
`
`5,231.60
`
`5,021.20
`
`5,113.80
`
`Advertising Expense
`
`1,000.00
`
`1,200.00
`
`1,100.00
`
`1,100.00
`
`https://investor.lilly.com/financial-information/fundamentals/income-statement
`
`3/37
`
`Novo Nordisk Exhibit 2529
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00003
`
`
`
`1/16/24, 2:09 AM
`
`Interactive Financials | Eli Lilly and Company
`
`Selling/General/Administrative Expenses, Total
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`6,440.40
`
`6,431.60
`
`6,121.20
`
`6,213.80
`
`Research & Development
`
`7,190.80
`
`7,025.90
`
`6,085.70
`
`5,595.00
`
`Purchased R&D Written-Off
`
`908.50
`
`874.90
`
`660.40
`
`239.60
`
`https://investor.lilly.com/financial-information/fundamentals/income-statement
`
`4/37
`
`Novo Nordisk Exhibit 2529
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00004
`
`
`
`1/16/24, 2:09 AM
`
`Interactive Financials | Eli Lilly and Company
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Restructuring Charge
`
`23.00
`
`13.00
`
`151.20
`
`77.80
`
`Impairment-Assets Held for Use
`
`221.60
`
`303.10
`
`-20.00
`
`497.80
`
`Other Unusual Expense (Income)
`
`0.00
`
`405.20
`
`--
`
`-57.30
`
`https://investor.lilly.com/financial-information/fundamentals/income-statement
`
`5/37
`
`Novo Nordisk Exhibit 2529
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00005
`
`
`
`1/16/24, 2:09 AM
`
`Interactive Financials | Eli Lilly and Company
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Unusual Expense (Income)
`
`1,153.10
`
`1,596.20
`
`791.60
`
`757.90
`
`Total Operating Expense
`
`21,414.10
`
`22,366.50
`
`18,481.80
`
`17,287.90
`
`Operating Income
`
`7,127.30
`
`5,951.90
`
`6,058.00
`
`5,031.60
`
`https://investor.lilly.com/financial-information/fundamentals/income-statement
`
`6/37
`
`Novo Nordisk Exhibit 2529
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00006
`
`
`
`1/16/24, 2:09 AM
`
`Interactive Financials | Eli Lilly and Company
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Interest Expense - Non-Operating
`
`-331.60
`
`-339.80
`
`-359.60
`
`-400.60
`
`Interest Capitalized - Non-Operating
`
`--
`
`--
`
`--
`
`--
`
`Interest Expense, Net Non-Operating
`
`-331.60
`
`-339.80
`
`-359.60
`
`-400.60
`
`https://investor.lilly.com/financial-information/fundamentals/income-statement
`
`7/37
`
`Novo Nordisk Exhibit 2529
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00007
`
`
`
`1/16/24, 2:09 AM
`
`Interactive Financials | Eli Lilly and Company
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Interest Income, Non-Operating
`
`62.80
`
`25.40
`
`33.00
`
`80.40
`
`Investment Income, Non-Operating
`
`-410.70
`
`176.90
`
`--
`
`--
`
`Interest/Investment Income, Non-Operating
`
`-347.90
`
`202.30
`
`33.00
`
`80.40
`
`https://investor.lilly.com/financial-information/fundamentals/income-statement
`
`8/37
`
`Novo Nordisk Exhibit 2529
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00008
`
`
`
`1/16/24, 2:09 AM
`
`Interactive Financials | Eli Lilly and Company
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Interest Income (Expense), Net-Non-Operating,
`Total
`
`-679.50
`
`-137.50
`
`-326.60
`
`-320.20
`
`Other Non-Operating Income (Expense)
`
`358.60
`
`341.10
`
`1,498.50
`
`554.50
`
`Other, Net
`
`358.60
`
`341.10
`
`1,498.50
`
`554.50
`
`https://investor.lilly.com/financial-information/fundamentals/income-statement
`
`9/37
`
`Novo Nordisk Exhibit 2529
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00009
`
`
`
`1/16/24, 2:09 AM
`
`Interactive Financials | Eli Lilly and Company
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Net Income Before Taxes
`
`6,806.40
`
`6,155.50
`
`7,229.90
`
`5,265.90
`
`Income Tax – Total
`
`561.60
`
`573.80
`
`1,036.20
`
`628.00
`
`Income After Tax
`
`6,244.80
`
`5,581.70
`
`6,193.70
`
`4,637.90
`
`https://investor.lilly.com/financial-information/fundamentals/income-statement
`
`10/37
`
`Novo Nordisk Exhibit 2529
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00010
`
`
`
`1/16/24, 2:09 AM
`
`Interactive Financials | Eli Lilly and Company
`
`Net Income Before Extraordinary Items
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`6,244.80
`
`5,581.70
`
`6,193.70
`
`4,637.90
`
`Discontinued Operations
`
`--
`
`0.00
`
`0.00
`
`3,680.50
`
`Extraordinary Item
`
`--
`
`--
`
`--
`
`--
`
`https://investor.lilly.com/financial-information/fundamentals/income-statement
`
`11/37
`
`Novo Nordisk Exhibit 2529
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00011
`
`
`
`1/16/24, 2:09 AM
`
`Interactive Financials | Eli Lilly and Company
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Total Extraordinary Items
`
`--
`
`0.00
`
`0.00
`
`3,680.50
`
`Net Income
`
`6,244.80
`
`5,581.70
`
`6,193.70
`
`8,318.40
`
`Income Available to Common Excluding
`Extraordinary Items
`
`6,244.80
`
`5,581.70
`
`6,193.70
`
`4,637.90
`
`https://investor.lilly.com/financial-information/fundamentals/income-statement
`
`12/37
`
`Novo Nordisk Exhibit 2529
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00012
`
`
`
`1/16/24, 2:09 AM
`
`Interactive Financials | Eli Lilly and Company
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Income Available to Common Stocks Including
`Extraordinary Items
`
`6,244.80
`
`5,581.70
`
`6,193.70
`
`8,318.40
`
`Basic Weighted Average Shares
`
`901.74
`
`906.96
`
`907.63
`
`931.06
`
`Basic EPS Excluding Extraordinary Items
`
`6.93
`
`6.15
`
`6.82
`
`4.98
`
`https://investor.lilly.com/financial-information/fundamentals/income-statement
`
`13/37
`
`Novo Nordisk Exhibit 2529
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00013
`
`
`
`1/16/24, 2:09 AM
`
`Interactive Financials | Eli Lilly and Company
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Basic EPS Including Extraordinary Items
`
`6.93
`
`6.15
`
`6.82
`
`8.93
`
`Diluted Net Income
`
`6,244.80
`
`5,581.70
`
`6,193.70
`
`8,318.40
`
`Diluted Weighted Average Shares
`
`904.62
`
`911.68
`
`912.51
`
`935.68
`
`https://investor.lilly.com/financial-information/fundamentals/income-statement
`
`14/37
`
`Novo Nordisk Exhibit 2529
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00014
`
`
`
`1/16/24, 2:09 AM
`
`Interactive Financials | Eli Lilly and Company
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Diluted EPS Excluding Extraordinary Items
`
`6.90
`
`6.12
`
`6.79
`
`4.96
`
`Diluted EPS Including Extraordinary Items
`
`6.90
`
`6.12
`
`6.79
`
`8.89
`
`DPS - Common Stock Primary Issue
`
`3.92
`
`3.40
`
`2.96
`
`2.58
`
`https://investor.lilly.com/financial-information/fundamentals/income-statement
`
`15/37
`
`Novo Nordisk Exhibit 2529
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00015
`
`
`
`1/16/24, 2:09 AM
`
`Interactive Financials | Eli Lilly and Company
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Gross Dividends - Common Stock
`
`3,667.50
`
`3,201.70
`
`2,786.20
`
`2,430.50
`
`Total Special Items
`
`1,153.10
`
`1,596.20
`
`791.60
`
`757.90
`
`Normalized Income Before Taxes
`
`7,959.50
`
`7,751.70
`
`8,021.50
`
`6,023.80
`
`https://investor.lilly.com/financial-information/fundamentals/income-statement
`
`16/37
`
`Novo Nordisk Exhibit 2529
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00016
`
`
`
`1/16/24, 2:09 AM
`
`Interactive Financials | Eli Lilly and Company
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Effect of Special Items on Income Taxes
`
`20.18
`
`67.24
`
`18.80
`
`61.81
`
`Income Taxes Excluding Impact of Special Items
`
`581.78
`
`641.04
`
`1,055.00
`
`689.81
`
`Normalized Income After Taxes
`
`7,377.72
`
`7,110.66
`
`6,966.50
`
`5,333.99
`
`https://investor.lilly.com/financial-information/fundamentals/income-statement
`
`17/37
`
`Novo Nordisk Exhibit 2529
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00017
`
`
`
`1/16/24, 2:09 AM
`
`Interactive Financials | Eli Lilly and Company
`
`Normalized Income Available to Common
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`7,377.72
`
`7,110.66
`
`6,966.50
`
`5,333.99
`
`Basic Normalized EPS
`
`8.18
`
`7.84
`
`7.68
`
`5.73
`
`Diluted Normalized EPS
`
`8.16
`
`7.80
`
`7.63
`
`5.70
`
`https://investor.lilly.com/financial-information/fundamentals/income-statement
`
`18/37
`
`Novo Nordisk Exhibit 2529
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00018
`
`
`
`1/16/24, 2:09 AM
`
`Interactive Financials | Eli Lilly and Company
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Amortization of Intangibles, Supplemental
`
`579.70
`
`628.80
`
`428.20
`
`225.80
`
`Depreciation, Supplemental
`
`942.80
`
`918.80
`
`895.70
`
`1,006.80
`
`Interest Expense, Supplemental
`
`331.60
`
`339.80
`
`359.60
`
`400.60
`
`https://investor.lilly.com/financial-information/fundamentals/income-statement
`
`19/37
`
`Novo Nordisk Exhibit 2529
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00019
`
`
`
`1/16/24, 2:09 AM
`
`Interactive Financials | Eli Lilly and Company
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Interest Capitalized, Supplemental
`
`--
`
`--
`
`--
`
`--
`
`Rental Expense, Supplemental
`
`148.80
`
`159.40
`
`154.60
`
`172.80
`
`Stock-Based Compensation, Supplemental
`
`371.10
`
`342.80
`
`308.10
`
`306.80
`
`https://investor.lilly.com/financial-information/fundamentals/income-statement
`
`20/37
`
`Novo Nordisk Exhibit 2529
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00020
`
`
`
`1/16/24, 2:09 AM
`
`Interactive Financials | Eli Lilly and Company
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Advertising Expense, Supplemental
`
`1,000.00
`
`1,200.00
`
`1,100.00
`
`1,100.00
`
`Equity in Affiliates, Supplemental
`
`-410.70
`
`176.90
`
`--
`
`--
`
`Research & Development Expense, Supplemental
`
`7,190.80
`
`7,025.90
`
`6,085.70
`
`5,595.00
`
`https://investor.lilly.com/financial-information/fundamentals/income-statement
`
`21/37
`
`Novo Nordisk Exhibit 2529
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00021
`
`
`
`1/16/24, 2:09 AM
`
`Interactive Financials | Eli Lilly and Company
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Audit-Related Fees, Supplemental
`
`13.90
`
`13.90
`
`13.70
`
`14.20
`
`Audit-Related Fees
`
`0.70
`
`0.70
`
`0.90
`
`0.70
`
`Tax Fees, Supplemental
`
`1.60
`
`2.10
`
`2.70
`
`2.70
`
`https://investor.lilly.com/financial-information/fundamentals/income-statement
`
`22/37
`
`Novo Nordisk Exhibit 2529
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00022
`
`
`
`1/16/24, 2:09 AM
`
`Interactive Financials | Eli Lilly and Company
`
`All Other Fees Paid to Auditor, Supplemental
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`--
`
`--
`
`--
`
`--
`
`Gross Margin
`
`76.77
`
`74.18
`
`77.66
`
`78.85
`
`Operating Margin
`
`24.97
`
`21.02
`
`24.69
`
`22.54
`
`https://investor.lilly.com/financial-information/fundamentals/income-statement
`
`23/37
`
`Novo Nordisk Exhibit 2529
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00023
`
`
`
`1/16/24, 2:09 AM
`
`Interactive Financials | Eli Lilly and Company
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Pretax Margin
`
`23.85
`
`21.74
`
`29.46
`
`23.59
`
`Effective Tax Rate
`
`8.25
`
`9.32
`
`14.33
`
`11.93
`
`Net Profit Margin
`
`21.88
`
`19.71
`
`25.24
`
`20.78
`
`https://investor.lilly.com/financial-information/fundamentals/income-statement
`
`24/37
`
`Novo Nordisk Exhibit 2529
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00024
`
`
`
`1/16/24, 2:09 AM
`
`Interactive Financials | Eli Lilly and Company
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Normalized EBIT
`
`8,280.40
`
`7,548.10
`
`6,849.60
`
`5,789.50
`
`Normalized EBITDA
`
`9,802.90
`
`9,095.70
`
`8,173.50
`
`7,022.10
`
`Current Tax - Domestic
`
`2,153.60
`
`938.50
`
`567.60
`
`280.20
`
`https://investor.lilly.com/financial-information/fundamentals/income-statement
`
`25/37
`
`Novo Nordisk Exhibit 2529
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00025
`
`
`
`1/16/24, 2:09 AM
`
`Interactive Financials | Eli Lilly and Company
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Current Tax - Foreign
`
`547.70
`
`466.00
`
`650.40
`
`299.80
`
`Current Tax - Local
`
`45.50
`
`-28.40
`
`-47.30
`
`-14.40
`
`Current Tax - Total
`
`2,746.80
`
`1,376.10
`
`1,170.70
`
`565.60
`
`https://investor.lilly.com/financial-information/fundamentals/income-statement
`
`26/37
`
`Novo Nordisk Exhibit 2529
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00026
`
`
`
`1/16/24, 2:09 AM
`
`Interactive Financials | Eli Lilly and Company
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Deferred Tax - Domestic
`
`-1,992.40
`
`-977.50
`
`-97.40
`
`141.30
`
`Deferred Tax - Foreign
`
`-78.20
`
`174.60
`
`-16.60
`
`-24.10
`
`Deferred Tax - Local
`
`-114.60
`
`0.60
`
`-20.50
`
`-54.80
`
`https://investor.lilly.com/financial-information/fundamentals/income-statement
`
`27/37
`
`Novo Nordisk Exhibit 2529
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00027
`
`
`
`1/16/24, 2:09 AM
`
`Interactive Financials | Eli Lilly and Company
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Deferred Tax - Total
`
`-2,185.20
`
`-802.30
`
`-134.50
`
`62.40
`
`Income Tax - Total
`
`561.60
`
`573.80
`
`1,036.20
`
`628.00
`
`Interest Cost - Domestic
`
`398.10
`
`337.80
`
`425.80
`
`486.00
`
`https://investor.lilly.com/financial-information/fundamentals/income-statement
`
`28/37
`
`Novo Nordisk Exhibit 2529
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00028
`
`
`
`1/16/24, 2:09 AM
`
`Interactive Financials | Eli Lilly and Company
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Service Cost - Domestic
`
`351.70
`
`369.20
`
`325.50
`
`250.40
`
`Prior Service Cost - Domestic
`
`2.40
`
`4.20
`
`4.50
`
`6.10
`
`Expected Return on Assets - Domestic
`
`-947.60
`
`-949.30
`
`-901.50
`
`-839.60
`
`https://investor.lilly.com/financial-information/fundamentals/income-statement
`
`29/37
`
`Novo Nordisk Exhibit 2529
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00029
`
`
`
`1/16/24, 2:09 AM
`
`Interactive Financials | Eli Lilly and Company
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Actuarial Gains and Losses - Domestic
`
`342.40
`
`487.70
`
`396.30
`
`284.90
`
`Curtailments & Settlements - Domestic
`
`--
`
`0.00
`
`0.00
`
`2.20
`
`Other Pension, Net - Domestic
`
`0.00
`
`0.00
`
`--
`
`0.00
`
`https://investor.lilly.com/financial-information/fundamentals/income-statement
`
`30/37
`
`Novo Nordisk Exhibit 2529
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00030
`
`
`
`1/16/24, 2:09 AM
`
`Interactive Financials | Eli Lilly and Company
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Domestic Pension Plan Expense
`
`147.00
`
`249.60
`
`250.60
`
`190.00
`
`Prior Service Cost - Foreign
`
`--
`
`--
`
`--
`
`--
`
`Foreign Pension Plan Expense
`
`--
`
`--
`
`--
`
`--
`
`https://investor.lilly.com/financial-information/fundamentals/income-statement
`
`31/37
`
`Novo Nordisk Exhibit 2529
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00031
`
`
`
`1/16/24, 2:09 AM
`
`Interactive Financials | Eli Lilly and Company
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Interest Cost - Post-Retirement
`
`37.80
`
`32.50
`
`43.70
`
`58.00
`
`Service Cost - Post-Retirement
`
`46.60
`
`49.20
`
`40.80
`
`36.30
`
`Prior Service Cost - Post-Retirement
`
`-54.80
`
`-59.60
`
`-59.50
`
`-62.90
`
`https://investor.lilly.com/financial-information/fundamentals/income-statement
`
`32/37
`
`Novo Nordisk Exhibit 2529
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00032
`
`
`
`1/16/24, 2:09 AM
`
`Interactive Financials | Eli Lilly and Company
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Expected Return on Assets - Post-Retirement
`
`-152.10
`
`-146.20
`
`-158.10
`
`-144.30
`
`Actuarial Gains and Losses - Post-Retirement
`
`0.90
`
`3.20
`
`-3.00
`
`1.90
`
`Curtailments & Settlements - Post-Retirement
`
`--
`
`--
`
`0.00
`
`0.00
`
`https://investor.lilly.com/financial-information/fundamentals/income-statement
`
`33/37
`
`Novo Nordisk Exhibit 2529
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00033
`
`
`
`1/16/24, 2:09 AM
`
`Interactive Financials | Eli Lilly and Company
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Other Post-Retirement, Net
`
`--
`
`--
`
`--
`
`0.00
`
`Post-Retirement Plan Expense
`
`-121.60
`
`-120.90
`
`-136.10
`
`-111.00
`
`Total Pension Expense
`
`25.40
`
`128.70
`
`114.50
`
`79.00
`
`https://investor.lilly.com/financial-information/fundamentals/income-statement
`
`34/37
`
`Novo Nordisk Exhibit 2529
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00034
`
`
`
`1/16/24, 2:09 AM
`
`Interactive Financials | Eli Lilly and Company
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Discount Rate - Domestic
`
`2.80
`
`2.40
`
`3.00
`
`4.00
`
`Discount Rate - Post-Retirement
`
`3.00
`
`2.60
`
`3.30
`
`4.40
`
`Expected Rate of Return - Domestic
`
`8.10
`
`6.80
`
`7.30
`
`7.40
`
`https://investor.lilly.com/financial-information/fundamentals/income-statement
`
`35/37
`
`Novo Nordisk Exhibit 2529
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00035
`
`
`
`1/16/24, 2:09 AM
`
`Interactive Financials | Eli Lilly and Company
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Expected Rate of Return - Post-Retirement
`
`7.30
`
`5.00
`
`6.00
`
`6.00
`
`Compensation Rate - Domestic
`
`3.50
`
`3.30
`
`3.30
`
`3.30
`
`Total Plan Interest Cost
`
`435.90
`
`370.30
`
`469.50
`
`544.00
`
`https://investor.lilly.com/financial-information/fundamentals/income-statement
`
`36/37
`
`Novo Nordisk Exhibit 2529
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00036
`
`
`
`1/16/24, 2:09 AM
`
`Interactive Financials | Eli Lilly and Company
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`Year Ending Dec 2022 (Update)
`
`Year Ending Dec 2021 (Update)
`
`Year Ending Dec 2020 (Update)
`
`Year Ending Dec 2019 (Update)
`
`In millions of USD (except for per share items); all data is GAAP
`
`Copyright Refinitiv
`
`Total Plan Service Cost
`
`398.30
`
`418.40
`
`366.30
`
`286.70
`
`Total Plan Expected Return
`
`-1,099.70
`
`-1,095.50
`
`-1,059.60
`
`-983.90
`
`Total Plan Other Expense
`
`0.00
`
`0.00
`
`--
`
`0.00
`
`https://investor.lilly.com/financial-information/fundamentals/income-statement
`
`37/37
`
`Novo Nordisk Exhibit 2529
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00037
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
